• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

    3/28/25 7:30:00 AM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LVTX alert in real time by email
    • Focused on the evaluation of strategic alternatives
    • Adopted a restructuring plan to extend capital resources, incurring a reduction in workforce of 30% to support the evaluation of strategic options and the Phase 1 study for LAVA-1266
    • Phase 1 enrollment in LAVA-1266 clinical trial underway
    • Johnson and Johnson development milestone of $5.0 million achieved and received in Q4 2024
    • Cash balance of $76.6 million as of December 31, 2024 expected to fund operations into 2027



    UTRECHT, The Netherlands and PHILADELPHIA, March 28, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX, "LAVA, " "the Company")), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced recent corporate highlights and financial results for the fourth quarter and year ended December 31, 2024.

    "LAVA's approach to maximize shareholder value in 2025 will focus on evaluating strategic options while continuing to enroll patients in our ongoing Phase 1 study of LAVA-1266, and supporting our pharma partnerships," said Steve Hurly, Chief Executive Officer of LAVA. "The Phase 1 study of LAVA-1266 as a potential treatment for acute myeloid leukemia and myelodysplastic syndrome is progressing. Looking ahead, with a strong cash balance, we believe LAVA is well-positioned to unlock strategic opportunities, and we look forward to updating investors with our progress throughout the year."

    Portfolio Highlights

    LAVA-1266 – Phase 1 Trial (ACTRN12624001214527)

    Designed to target CD123+ tumor cells for the treatment of hematological malignancies

    • Key indications: Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)
    • Current Status: LAVA is enrolling patients in the second dose level at 300 µg in a first-in-human Phase 1, open label, multi-center study in Australia. The study includes a dose escalation and dose expansion segment to evaluate LAVA-1266 in approximately 50 adults with CD123+ relapsed/refractory AML or intermediate, high or extremely high risk MDS.



      The study is evaluating safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity and preliminary anti-tumor activity.

    Johnson & Johnson (J&J) Partnered Program (JNJ-89853413) – Phase 1 Trial (NCT06618001)

    Designed to target CD33 and gamma delta T cells with a bispecific gamma delta T cell engager

    • Key Indications: Include hematological cancers
    • Current Status: J&J is enrolling patients in a Phase 1, open label, multi-center study underway in Canada and Spain. The study includes a dose escalation and dose expansion segment to evaluate JNJ-89853413 in approximately 100 adults with relapsed/refractory AML or moderate or higher risk MDS. The study is evaluating safety, tolerability, PK, PD, immunogenicity and preliminary anti-tumor activity.



      J&J presented preclinical data for JNJ-89853413 at the Annual Meeting of the American Society of Hematology (ASH 2024) on December 7, 2024 (Abstract 2054).
    • Milestone: Development milestone of $5 million received from J&J in Q4 2024 related to the IND filing for JNJ-89853413

    Pfizer Partnered Program (PF08046052) – Phase 1 Trial (NCT05983133) 

    Potential first-in-class epidermal growth factor receptor (EGFR) and bispecific gamma delta T cell receptor-targeted therapy for solid tumors

    • Key Indications: Include colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and pancreatic ductal adenocarcinoma (PDAC)
    • Current Status: Pfizer is enrolling patients in a Phase 1 open label, multi-center study, underway in the U.S. and UK. The study will include dose escalation and dose expansion segments to evaluate PF08046052 in approximately 275 subjects with metastatic, non-resectable solid tumor cancers. The study will evaluate safety, tolerability, PK, immunogenicity and preliminary anti-tumor activity.
    • Milestone: Clinical development milestone of $7 million received from Pfizer in Q1 2024



    Fourth Quarter and Year-End 2024 Financial Results

    • In February 2025, the Company adopted a restructuring plan to extend its capital resources in connection with initiating a process to evaluate strategic alternatives. As part of the restructuring plan, the Company's board of directors approved a reduction of approximately 30% of the Company's global workforce to better align resources with the Company's focus on the evaluation of strategic options and the Phase 1 study for LAVA-1266. The Company expects approximately $1.0 million of expenses related to the restructuring to be incurred during the six months ended June 30, 2025, of which approximately $0.3 million of cash payments are expected to be made during 2025.
    • As of December 31, 2024, LAVA had cash, cash equivalents, and investments of $76.6 million, compared to cash, cash equivalents, and investments of $95.6 million as of December 31, 2023. The Company believes its current cash, cash equivalents and investments will be sufficient to fund operations into 2027.
    • Revenue from contracts with customers was $5.0 million and $0.4 million for the quarters ended December 31, 2024 and 2023, respectively, and $12.0 million and $6.8 million for the years ended December 31, 2024 and 2023, respectively. The increase in revenue for the quarter ended December 31, 2024 compared to 2023 was primarily due to the $5.0 million milestone related to J&J's IND filing in October 2024. The increase in revenue for the year ended December 31, 2024 compared to 2023 was primarily related to $7.0 million the Company recognized in revenue in connection with its agreement with Pfizer related to the achievement of a clinical development milestone and $5.0 million the Company recognized as revenue in connection with J&J's IND filing. In comparison, in 2023, revenue included $4.3 million related to the Company's agreement with Pfizer and $2.5 million related to the Company's agreement with J&J.
    • Cost of sales of goods and providing services was zero and $0.2 million for the quarters ended December 31, 2024 and 2023, respectively, and zero and $3.5 million for the years ended December 31, 2024 and 2023, respectively. The cost in 2023 was due to the initial drug supply delivery to Pfizer and related stability studies.
    • Research and development expenses were $8.6 million and $2.3 million for the quarters ended December 31, 2024 and 2023, respectively, and $28.5 million and $32.6 million for the years ended December 31, 2024 and 2023, respectively. The increase for the quarter ended December 31, 2024, as compared to December 31, 2023, was primarily due to costs associated with the discontinuation of LAVA-1207, announced in December 2024. The decrease for the year ended December 31, 2024, as compared to December 31, 2023, was primarily due to reduced manufacturing scale-up costs and headcount reductions that occurred in the second half of 2023, offset by costs associated with the discontinuation of LAVA-1207.
    • General and administrative expenses were $3.3 million for each of the quarters ended December 31, 2024 and 2023, and $13.2 million and $14.1 million for the years ended December 31, 2024 and 2023, respectively. The decrease for the year ended December 31, 2024, as compared to December 31, 2023, was primarily due to lower share-based compensation expense as a result of fewer options issued and a reduction in the Company's share price.
    • Net loss was $3.8 million and $6.4 million for the quarters ended December 31, 2024 and 2023, respectively, or $0.14 and $0.24 net loss per share for the quarters ended December 31, 2024 and 2023, respectively. Net losses were $25.1 million and $41.9 million for the years ended December 31, 2024 and 2023, respectively, or $0.94 and $1.57 net loss per share for the years ended December 31, 2024 and 2023, respectively.





                
    LAVA Therapeutics N.V.

    Condensed Consolidated Statements of Operations and Comprehensive Loss

    (in thousands, except share and per share amounts) (unaudited)
                
     Three Months Ended Year Ended
     December 31,  December 31, 
     2024    2023 2024    2023 
    Revenue:             
    Revenue from contracts with customers$4,990 $353 $11,982 $6,769
    Total revenue 4,990  353  11,982  6,769
    Cost and expenses:             
    Cost of revenue —  (155)  —  (3,482)
    Research and development (8,568)  (2,302)  (28,450)  (32,559)
    General and administrative (3,344)  (3,300)  (13,225)  (14,122)
    Total cost and expenses (11,912)  (5,758)  (41,675)  (50,163)
    Operating loss (6,922)  (5,405)  (29,693)  (43,394)
    Other income (expense), net           
    Interest income 863  1,002  3,758  3,672
    Interest expense (125)  (117)  (515)  (470)
    Foreign currency exchange gain (loss), net 2,688  (1,851)  1,966  (1,422)
    Total other income (expense), net 3,427  (966)  5,209  1,780
    Net loss before taxes (3,495)  (6,370)  (24,484)  (41,614)
    Income tax expense, net (379)  (37)  (630)  (257)
    Net loss$(3,874) $(6,408) $(25,114) $(41,871)
    Other comprehensive (expense) income:           
    Foreign currency translation adjustment (2,054)  2,159  (1,758)  2,075
    Comprehensive loss$(5,928) $(4,249) $(26,872) $(39,796)
                
                  
    Net loss per share, basic and diluted$(0.14) $(0.24) $(0.94) $(1.57)
    Weighted-average common shares outstanding, basic and diluted 26,866,931  26,769,937  26,834,422  26,732,556
                
                



           
    LAVA Therapeutics N.V.

    Condensed Consolidated Balance Sheets

    (in thousands) (unaudited)
           
      As of December 31,
      2024    2023
    Assets         
    Current assets:      
    Cash and cash equivalents $35,015 $44,231
    Short-term investments  41,561  51,340
    Prepaid expenses  1,072  1,627
    Other current assets  1,649  1,699
    Total current assets  79,297  98,897
    Property and equipment, net  1,002  1,602
    Operating lease right-of-use assets  441  855
    Other non-current assets  91  319
    Total assets $80,831 $101,673
    Liabilities and shareholders' equity      
    Current liabilities:      
    Accounts payable $2,722 $4,446
    Accrued expenses and other current liabilities  10,083  4,751
    Borrowings  4,886  5,282
    Current portion of operating lease liabilities  315  415
    Total current liabilities  18,006  14,894
    Non-current portion of deferred revenue  35,000  35,000
    Non-current portion of operating lease liabilities  80  415
    Total liabilities  53,086  50,309
    Commitments and contingencies      
    Shareholders' equity:      
    Common stock  3,717  3,715
    Additional paid-in capital  211,656  208,405
    Accumulated deficit  (174,973)  (149,859)
    Accumulated other comprehensive loss  (12,655)  (10,897)
    Total shareholders' equity  27,745  51,364
    Total liabilities and shareholders' equity $80,831 $101,673
           



    About LAVA Therapeutics

    LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company focused on advancing its proprietary Gammabody® platform to develop a portfolio of bispecific gamma-delta T cell engagers for the potential treatment of solid tumors and hematologic malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering Vγ9Vδ2 (Vgamma9 Vdelta2) T cell anti-tumor effector functions upon cross-linking to tumor-associated antigens.

    LAVA's pipeline includes three internal and partnered clinical-stage bispecific gamma-delta T cell engagers for the treatment of solid tumor and hematological cancers including LAVA 1266, targeting CD123+ cancers (ACTRN12624001214527); PF-08046052, targeting EGFR (NCT05983133); and JNJ-89853413, targeting hematological cancers (NCT06618001). The pipeline also includes preclinical programs. For more information on LAVA, please visit our website at www.lavatherapeutics.com or follow us on LinkedIn, X, and YouTube.

    Gammabody® is a registered trademark of LAVA Therapeutics N.V.

    LAVA's Cautionary Note on Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate", "believe", "could", "will", "may", "expect", "should", "plan", "intend", "estimate", "potential", "suggests", and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on LAVA's expectations and assumptions as of the date of this press release and are subject to various risks and uncertainties that may cause actual results to differ materially from these forward-looking statements. Forward-looking statements contained in this press release include but are not limited to statements relating to LAVA's evaluation of strategic alternatives and transactions to maximize shareholder value, LAVA's ability to preserve capital and the sufficiency of cash on hand, the reduction in force, as well as the therapeutic potential, development strategy and potential uses of LAVA's product candidates, including LAVA-1266, the timing of initiation of clinical trials and achievement of clinical milestones, LAVA's cash runway and the sufficiency of resources to pursue development activities, progress and data from clinical trials, and the ability of LAVA's product candidates to treat various tumor targets and improve patient outcomes, among others. Many factors, risks and uncertainties may cause differences between current expectations and actual results, including, among other things, the Company's ability to leverage its initial programs to develop additional product candidates using its Gammabody® platform, the failure of LAVA's collaborators to support or advance collaborations or LAVA's product candidates, the timing and results of LAVA's research and development programs and preclinical and clinical trials, the possibility that clinical trials may fail to establish sufficient efficacy, the risk that adverse events or safety signals may occur in clinical trials, the risk that results obtained in preclinical studies or clinical trials to date may not be indicative of results obtained in ongoing or future trials, the risk that adverse regulatory actions or other setbacks could occur in clinical trials even after promising results in earlier clinical trials or preclinical studies, the Company's ability to obtain regulatory approval for and commercialize its product candidates, LAVA's ability to identify any strategic alternatives or if so identified, be able to consummate any such transactions on terms acceptable to LAVA and its shareholders, and the risk that setbacks in development could occur as a result of the difficulty and uncertainty of pharmaceutical product development and other factors. There may be adverse effects on the Company's business condition and results from general economic and market conditions and overall fluctuations in the United States and international equity markets, including as a result of inflation, heightened interest rates, recent and potential future pandemics and other health crises, and hostilities, including the Russian invasion of Ukraine and the conflict in the Middle East.  These and other risks are described in greater detail under the caption "Risk Factors" in LAVA's most recent Annual Report on Form 10-K and other filings the Company makes with the Securities and Exchange Commission. LAVA assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

    CONTACTS

    Investor Relations

    [email protected]

    LifeSci Advisors (IR/Media)

    Joyce Allaire

    [email protected]



    Primary Logo

    Get the next $LVTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LVTX

    DatePrice TargetRatingAnalyst
    12/12/2024$11.00 → $2.00Outperform → Market Perform
    Leerink Partners
    12/11/2024Mkt Outperform → Mkt Perform
    JMP Securities
    10/25/2022$9.00Buy
    H.C. Wainwright
    11/16/2021$24.00 → $20.00Outperform
    SVB Leerink
    8/17/2021$26.00 → $24.00Outperform
    SVB Leerink
    More analyst ratings

    $LVTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • LAVA Therapeutics downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded LAVA Therapeutics from Outperform to Market Perform and set a new price target of $2.00 from $11.00 previously

      12/12/24 8:11:38 AM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LAVA Therapeutics downgraded by JMP Securities

      JMP Securities downgraded LAVA Therapeutics from Mkt Outperform to Mkt Perform

      12/11/24 7:55:00 AM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on LAVA Therapeutics with a new price target

      H.C. Wainwright initiated coverage of LAVA Therapeutics with a rating of Buy and set a new price target of $9.00

      10/25/22 6:28:17 AM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LVTX
    Leadership Updates

    Live Leadership Updates

    See more
    • LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directors

      UTRECHT, The Netherlands and PHILADELPHIA, March 09, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers, today announced the appointment of Christy J. Oliger to its board of directors effective March 9, 2023. Ms. Oliger brings extensive commercial, portfolio management, and senior leadership experience to the role. Additionally, Stefan Luzi, Ph.D., will step down from his role on the LAVA Board. "As an accomplished leader in the pharmaceutical and biotechnology industry with deep experience in oncology, Ms. Oliger brings over three deca

      3/9/23 8:05:00 AM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical Officer

      UTRECT, The Netherlands and PHILADELPHIA, Feb. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that Dr. Charles Morris has joined LAVA as chief medical officer effective February 6, 2023. Dr. Morris will replace Benjamin Winograd, MD, PhD. "During a 25-year tenure in the industry, Dr. Morris has demonstrated a proven track record of advancing novel oncology product candidates from clinical development through global regulatory approvals," said Stephen Hurly, president and chief executive offi

      2/6/23 7:00:00 AM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results

      LAVA-051 updated interim data from ongoing Phase 1/2a clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia and multiple myeloma to be presented at 2022 American Society of Hematology (ASH) Annual MeetingPresented LAVA-051 clinical pharmacodynamic data demonstrating consistency with mechanism of action data at the Society for Immunotherapy for Cancer (SITC) 2022 Annual MeetingAnnounced exclusive worldwide license agreement with Seagen to advance LAVA-1223, a preclinical bispecific gamma delta T cell engager for EGFR-expressing solid tumorsCash and investments of $92.7 million as of September 30, 2022, plus$50.0 million received from Seagen in October provide cas

      11/16/22 4:05:00 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LVTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Cooperatieve Gilde Healthcare Iv U.A. claimed ownership of 5,421,170 shares (SEC Form 3)

      3 - LAVA Therapeutics NV (0001840748) (Issuer)

      4/8/25 6:19:03 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Wilson Karen J

      4 - LAVA Therapeutics NV (0001840748) (Issuer)

      2/18/25 8:15:24 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Kiener Peter A

      4 - LAVA Therapeutics NV (0001840748) (Issuer)

      2/18/25 8:15:17 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LVTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation

      Exemption from the $5.1 million repayment obligation strengthens LAVA's balance sheet Underscores focus on cost curtailment and strategic option evaluation UTRECHT, The Netherlands and PHILADELPHIA, April 16, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX, "LAVA, " "the Company")), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced that the Netherlands Enterprise Agency (Rijksdienst voor Ondernemend Nederland, RVO) granted a full waiver of the final payment obligation related to the Innovation Credit, in the amount of $5.1 million. "As part of LAVA's ongoing strategic

      4/16/25 7:30:00 AM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

      Focused on the evaluation of strategic alternativesAdopted a restructuring plan to extend capital resources, incurring a reduction in workforce of 30% to support the evaluation of strategic options and the Phase 1 study for LAVA-1266Phase 1 enrollment in LAVA-1266 clinical trial underwayJohnson and Johnson development milestone of $5.0 million achieved and received in Q4 2024Cash balance of $76.6 million as of December 31, 2024 expected to fund operations into 2027 UTRECHT, The Netherlands and PHILADELPHIA, March 28, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX, "LAVA, " "the Company")), a clinical-stage immuno-oncology company focused on developing its proprietary Gammab

      3/28/25 7:30:00 AM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LAVA Announces Evaluation of Strategic Options

      Advisor engaged in evaluating strategic options to maximize shareholder value Cash balance of $76.6 million as of December 31, 2024 UTRECHT, The Netherlands and PHILADELPHIA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX, "LAVA, " "the Company")), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, announced that the Company has initiated a process to review strategic options focused on maximizing shareholder value and has implemented cost curtailment including a workforce reduction. The Company has retained an experienced financial advisor to

      2/25/25 7:00:00 AM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LVTX
    Financials

    Live finance-specific insights

    See more
    • LAVA Therapeutics to Present Initial Phase 1/2a Clinical Trial Dose Escalation Data of LAVA-051 in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

      UTRECHT, The Netherlands and PHILADELPHIA, June 01, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced the presentation of initial dose-escalation data from the Phase 1/2a clinical trial of LAVA-051 in patients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago and virtually June 3-7, 2022. "These dose-escalation data from the first four cohorts of our Phase 1/2a clinical tria

      6/1/22 7:00:00 AM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LVTX
    SEC Filings

    See more
    • SEC Form DEF 14A filed by LAVA Therapeutics N.V.

      DEF 14A - LAVA Therapeutics NV (0001840748) (Filer)

      4/28/25 4:08:57 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by LAVA Therapeutics N.V.

      PRE 14A - LAVA Therapeutics NV (0001840748) (Filer)

      4/15/25 4:23:35 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by LAVA Therapeutics N.V.

      S-8 - LAVA Therapeutics NV (0001840748) (Filer)

      3/28/25 4:47:54 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LVTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by LAVA Therapeutics N.V. (Amendment)

      SC 13D/A - LAVA Therapeutics NV (0001840748) (Subject)

      3/7/24 7:09:56 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by LAVA Therapeutics N.V. (Amendment)

      SC 13G/A - LAVA Therapeutics NV (0001840748) (Subject)

      2/14/24 4:26:22 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by LAVA Therapeutics N.V. (Amendment)

      SC 13D/A - LAVA Therapeutics NV (0001840748) (Subject)

      11/9/23 4:37:57 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care